"10.1371_journal.pone.0099404","plos one","2014-06-05T00:00:00Z","Longchuan Bai; Jianfang Chen; Donna McEachern; Liu Liu; Haibin Zhou; Angelo Aguilar; Shaomeng Wang","University of Michigan Comprehensive Cancer Center and Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America; University of Michigan Comprehensive Cancer Center and Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, United States of America; University of Michigan Comprehensive Cancer Center and Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan, United States of America","Conceived and designed the experiments: SW LB. Performed the experiments: LB JC DM LL. Analyzed the data: LB SW. Contributed reagents/materials/analysis tools: HZ AA. Wrote the paper: LB SW.","Ascentage Pharma has licensed the Bcl-2/Bcl-XL inhibitor technology from the University of Michigan. Dr. Wang receives compensation and owns stock in Ascentage. All other authors declare no conflict of interest. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2014","06","Longchuan Bai","LB",7,TRUE,2,4,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
